[go: up one dir, main page]

WO2012050397A2 - Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein - Google Patents

Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein Download PDF

Info

Publication number
WO2012050397A2
WO2012050397A2 PCT/KR2011/007675 KR2011007675W WO2012050397A2 WO 2012050397 A2 WO2012050397 A2 WO 2012050397A2 KR 2011007675 W KR2011007675 W KR 2011007675W WO 2012050397 A2 WO2012050397 A2 WO 2012050397A2
Authority
WO
WIPO (PCT)
Prior art keywords
kidney cancer
composition
weight
parts
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/007675
Other languages
English (en)
Korean (ko)
Other versions
WO2012050397A3 (fr
Inventor
황성연
안성훈
서근영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOREA BIO MEDICAL SCIENCE INSTITUTE
Original Assignee
KOREA BIO MEDICAL SCIENCE INSTITUTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOREA BIO MEDICAL SCIENCE INSTITUTE filed Critical KOREA BIO MEDICAL SCIENCE INSTITUTE
Publication of WO2012050397A2 publication Critical patent/WO2012050397A2/fr
Publication of WO2012050397A3 publication Critical patent/WO2012050397A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating kidney cancer, comprising a herbal extract, and more particularly, including extracts of red ginseng, Angelica, Schisandra chinensis, Tosa and turmeric as active ingredients, and having high antioxidant activity, in particular
  • the present invention relates to a pharmaceutical composition for preventing or treating kidney cancer having an excellent anticancer effect against kidney cancer.
  • Kidney cancer (renal cell carcinoma) accounts for 3% of adult cancer in the United States, with approximately 32,000 new cases per year and an estimated 12,000 deaths from renal cell cancer. The frequency of occurrence is increasing. In Korea, according to the 2002 Central Cancer Registration Data, 1,587 new patients were registered, accounting for 1.6% of all cancer cases. In particular, men are twice as likely as women, and in 2002, 1104 patients occurred in men, which is the 10th most common cancer with a long-term enrollment rate of 2.0%.
  • kidney cancer The treatment methods for kidney cancer known to date are determined by the progression of the cancer, the age of the patient, the general condition, and the presence of other diseases associated with it. In general, it is difficult to respond to radiation therapy or chemotherapy. Although it is best to get rid of cancer, side effects such as bleeding, infection, and postoperative pain can occur along with ileus, pneumothorax, and embolism. Even when immunochemotherapy is performed, hypersensitivity to immunosuppressants, chills and fever, nausea and vomiting, general weakness, anorexia, headache, anemia and leukopenia may occur.
  • DEN diethylnitrosamine
  • the "military clergy theory" ( ⁇ ⁇ ⁇ ) is the basic principle of the composition of the control, which is modeled after the rule of the ancient monarchy system. In oriental medicine, this principle is applied, and each ingredient plays a unique role to treat the whole harmony and balance.
  • Herbal medicines which were used for the treatment of various diseases, have not been developed as a method of refining them due to impurity, but they have been developed from simply taking one type of drug like Dokticianang to taking various types of drugs, suggesting a great development of liver control. can do.
  • Predecessors have recognized that there are a great variety of factors that control the human body, and it is more beneficial to control various factors in the body with different drugs than simply or one important factor in how to control disease or pain. It can be concluded that the empirical knowledge of the predecessors is concentrated.
  • Each herbal material included in the composition of the present invention may be used without limitation, such as cultivated or commercially available, and can be extracted or used as it is in a dry or natural state.
  • the herbal extract of the present invention exhibits anticancer activity against kidney cancer by inhibiting renal cell damage caused by oxidative stress.
  • the pharmaceutical composition of the present invention can be confirmed that inhibits renal cell damage by DEN (diethylnitrosamine) known as a carcinogen causing long-term damage by oxidative stress.
  • DEN diethylnitrosamine
  • composition of the present invention may further include various other types of herbal extracts for enhancing the pharmacological anticancer effect of the herbal extracts, in addition to the herbal extracts of the red ginseng, goji berry, cornus oil, Schisandra chinensis, bokbunja, earth and sand, turmeric, and Angelica as active ingredients. have.
  • Herbal extracts that may be additionally included in the composition of the present invention include pharmaceutically acceptable herbal medicines, including Gobon, Cheonma, Shiho, Doin, Gyeji, Rhubarb, Licorice, Cheongung, Dermis, Taxa, Hulk, Golden, Bokyeong, Peony, Baekchul, Hwangbaek, Gardenia, Banja, Morning Light, Jisil, Ginseng, Macmun-dong, Wonji, Seokchangpo, Creation, Gamkook, Windproof, Ginger, Forget-me-not, Contrast, Sweet Ginseng, Barberry, Chihwang, Mint, Mountain Fertilizer, Spirit, Shou, Guja, Absolute, Poisonous life, tofu, baekryeoksaengcho, three hundred seconds, jinjin, jimo, safflower, Astragalus, calendula, ginkgo biloba, hwangjeong, lotus root, ke
  • the composition may be prepared by filling the herbal extract with no excipient in the capsule or uniformly and sufficiently in contact with the atomized solid carrier, liquid carrier or both, and, if necessary, the product may be molded into a desired formulation.
  • suitable carrier excipients include starch, water, saline, ethanol, glycerol, Ringer's solution and dextrose solution, and the like (Remington's Pharmaceutical Science, 19 th Ed., 1995, Mack Publishing Company, Easton PA) and the like. As disclosed, it may be formulated into a suitable formulation known in the art.
  • composition of the present invention can be applied to any formulation containing it as an active ingredient, it can be prepared in oral or parenteral formulations.
  • Pharmaceutical formulations of the invention may be oral, rectal, nasal, topical (including the cheek and sublingual), subcutaneous, vaginal or parenteral (intramuscular, subcutaneous). And forms suitable for administration by inhalation or insufflation.
  • Oral dosage forms containing the composition of the present invention as an active ingredient include, for example, tablets, troches, lozenges, water-soluble or oily suspensions, preparation powders or granules, emulsions, hard or soft capsules, syrups or elixirs. can do.
  • suppositories For infusion into suppositories, it may be formulated as a rectal composition such as suppositories or body enema including conventional suppository bases such as cocoa butter or other glycerides.
  • a propellant or the like When formulated for spraying such as aerosols, a propellant or the like may be combined with the additives to disperse the dispersed dispersion or wet powder.
  • the pharmaceutical composition of the present invention comprises arithmetic and Angelica known as the main constituents of the resonant stage, which is a representative herbal medicine, and contains other herbal medicines, that is, red ginseng, wolfberry, Schisandra chinensis, bokbunja, earthenware and turmeric in an appropriate amount, Since it exhibits anti-cancer activity, it can be used to manufacture anti-cancer resonators for the prevention or treatment of kidney cancer. Therefore, the composition of the present invention is particularly preferably processed in the form of pills.
  • the pill form is concentrated by extracting the herbal medicine and then finely pulverizing each medicine by using a grinder to mix the extract and powder, and put the powder mixed with the chemical liquid again into a grinder to filter the fine particles 300-500mesh sieve fine particles
  • Herbs made of round, sweet and round can be packaged again using edible gold leaf (or silver leaf).
  • Gold or silver has long been used in making pills to stabilize the mind and have been used as an auxiliary material in prescriptions such as resonant stages and cow sulfur cheongsimwon with the effect of insect repellent protection.
  • the process of making the ring in the other form is the same, and has been used as a dye from herbal medicines such as porcelain and salvia and has been used as a dye from the past, and can be used by coating the surface to extract the effective insect repellent.
  • the term "administration" means introducing a pharmaceutical composition of the present invention to a patient in any suitable manner, and the route of administration of the composition of the present invention may be various oral or parenteral routes as long as it can reach the desired tissue. It may be administered through, or specifically, can be administered in a conventional manner via oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, nasal, inhalation, intraocular or intradermal route. . Preferably oral administration.
  • the specific therapeutically effective amount for a particular patient may be based on the specific composition, including the type and severity of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health, sex and diet of the patient, time of administration, It is desirable to apply differently depending on the route of administration and the rate of release of the composition, the duration of treatment, and the various factors and similar factors well known in the medical arts, including drugs used with or concurrent with the specific composition. Therefore, the effective amount of a pharmaceutical composition suitable for the purpose of the present invention is preferably determined in consideration of the above matters. However, for the desired effect, the compound of the present invention may be administered in an amount of 0.0001 to 100 mg / kg, preferably 0.01 to 10 mg / kg, divided once to several times daily.
  • kidney cancer of the present invention is applicable to any animal in which kidney cancer may occur, and the animal may be used for livestock such as cattle, pigs, sheep, horses, dogs, and cats, as well as humans and primates. Include.
  • the composition preferably comprises extracts of red ginseng, goji berry, cornus oil, Schisandra chinensis, bokbunja, earth and sand, turmeric, and Angelica as active ingredients.
  • composition of the present invention may be added to a dietary supplement for the purpose of preventing or improving kidney cancer.
  • each herbal material included in the composition may be used in a manner of additionally adding the powder itself in addition to the extract form.
  • the pharmaceutical composition of the present invention can be prepared as a health functional food in the form of a preparation by further comprising a food additive acceptable food formulation, the form of the preparation can be tablets, capsules, pills, liquids and the like. .
  • beverages including alcoholic beverages
  • fruits and processed foods e.g. canned fruit, canned foods, jams, marmalade, etc.
  • fish meat and processed foods
  • meat and processed foods e.g. ham, sausage cornebi, etc.
  • Breads and noodles e.g. udon, soba, ramen, spaghetti, macaroni, etc.
  • fruit juices various drinks, cookies, malts, dairy products (e.g.
  • the health functional food of the present invention is a variety of flavors, natural carbohydrates, sweeteners, vitamins, electrolytes, colorants, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonating agents And the like may be further contained.
  • the natural carbohydrate may be a sugar such as glucose, monosaccharides such as fructose, maltose, disaccharides such as sucrose, polysaccharides such as dextrin, cyclodextrin, xylitol, sorbitol, and erythritol.
  • the pharmaceutical composition for preventing or treating kidney cancer of the present invention has an antioxidant activity and exhibits an anti-cancer effect through inhibiting lung cell damage caused by oxidative stress, thereby preventing or treating kidney cancer. It can be usefully used in the preparation of the formulation and dietary supplements.
  • the pharmaceutical composition is excellent in texture when processed into a pill form can be used in the manufacture of anti-cancer diagnostics for the treatment or prevention of kidney cancer.
  • the combination of the present invention is more significant in terms of military history and overall immunity.
  • Figure 6 is a graph measuring the measurement of SOD (Superoxide dismutase) -like activity of the herbal extract according to the present invention.
  • FIG. 8 is a graph evaluating the effect of the herbal extract according to the present invention on LDH activity of rats induced kidney cancer.
  • ACHN human kidney cancer cell line was used by the National Cancer Center.
  • the kidney cancer cell lines were cultured in MEM culture medium containing 10% FBS and penicillin, streptomycin, 25 mM HEPES, 1 mM sodium pyruvate.
  • each well was dispensed into ACHN human kidney cancer cell lines (6.5x10 3 cells) per 96 well plate and cultured. After 24 hours, each extract of the culture solution was diluted to a predetermined concentration and injected into each well. After 48 hours of further incubation, the viability of the cells was confirmed with PrestoBlue (Invitrogen) reagent.
  • PrestoBlue Invitrogen
  • red ginseng 6-year-old ethanol extract in Ganghwa-do on the cell viability of kidney cancer cell line (ACHN) at various concentrations showed that red ginseng ethanol extract did not directly affect the survival rate of kidney cancer cells.
  • the concentration of red ginseng ethanol extract observed in the experiment was observed from about 160 mg / ml to 5 mg / ml, and the cell survival rate of 84.5% was not reached until the concentration of 160 mg / ml (Fig. 1A). ).
  • the effects of red ginseng and the concentration of donkey and turmeric on the cell survival rate of kidney cancer cell lines were as follows.
  • the cell viability at M2 concentration was about 103.3%
  • the cell viability at M3 concentration was about 99.1%
  • the cell viability at M4 concentration was 102.3%
  • the cell viability at M5 concentration was about 93.3%
  • the cell viability at M6 concentration was Cell viability at about 76.3% and M7 concentration was observed at about 60.7% (FIG. 2D).
  • the effects of red ginseng, Angelica, sediment, and turmeric on the cell survival rate of kidney cancer cell lines were as follows.
  • the cell viability at the M1 concentration of the untreated group was converted to 100.0%
  • the cell viability at the M2 concentration was about 100.7%
  • the cell viability at the M3 concentration was about 103.4%
  • the cell viability at the M4 concentration was about 105.6%
  • the cell viability at M5 concentration was about 96.2%
  • the cell viability at M6 concentration was about 81.9%
  • the cell viability at M7 concentration was about 66.9% (FIG. 2F).
  • the effects of red ginseng, Angelica, Schisandra chinensis, Tosa, and turmeric on the cell survival rate of kidney cancer cell lines were as follows.
  • the cell viability at the M1 concentration of the untreated group was converted to 100.0%
  • the cell viability at the M2 concentration was about 103.7%
  • the cell viability at the M3 concentration was about 105.8%
  • the cell viability at the M4 concentration was about 104.9%
  • the cell viability at M5 concentration was about 102.0%
  • the cell viability at M6 concentration was about 92.7%
  • the cell viability at M7 concentration was about 68.0% (Fig. 2G).
  • red ginseng, wolfberry, cornus oil, Schisandra chinensis, bokbunja, earth and sand, turmeric and Angelica were purchased and then ground.
  • the powdered herbal medicines were made to have a total herbal weight of 1 kg in the composition of Table 2, and then extracted with 4 L of 100% methanol at 70 ° C. for 3 hours using an extractor to prepare a herbal extract.
  • the 100% methanol extract prepared in the above ⁇ 4-1> process was prepared in five fractions by separating the polar solvent from the nonpolar solvent in the order of polar solvent using the polarity difference of the solvent in the same manner as in FIG. 4.
  • the methanol extract was concentrated under reduced pressure, n-hexane and water were mixed and dissolved in the separatory funnel to obtain an n-hexane fraction layer.
  • the aqueous layer was placed in a separatory funnel, and chloroform, ethyl acetate, n-butanol and aqueous fractions were sequentially obtained in the same manner.
  • the methanol extract, the hexane fraction, the chloroform fraction, the ethyl acetate fraction, the butanol fraction, and the extract of the aqueous layer were then concentrated under reduced pressure, lyophilized, and the yield of each fraction was determined by gravimetric method.
  • Each fraction extract was stored frozen at -70 °C was used in the experiment.
  • the herbal extract thus obtained was named 'anticancer diagnostic diagnosis extract'.
  • Age rats (Rat, Sprague Dawley) of about 180 ⁇ 10 g body weight were purchased from Samtaco (Osan, Korea). The experimental animals were supplied with sufficient solid food (for cryingaco, rats) and water under certain conditions (temperature: 21 ⁇ 2 °C, humidity: 50-60%, 12 hours light / dark cycle) in the animal breeding room of Wonkwang University. Adapted for 1 week while being used in the experiment.
  • oxidative stress The formation and development of cancer by oxidative stress is well known.
  • the main mechanism of DEN stimulation a carcinogen, is in inducing oxidative stress. Therefore, the present inventors confirmed the degree of oxidative stress inhibition to determine whether the herbal extracts can inhibit oxidative stress.
  • ABST method is the most frequently used method of indirect one of the antioxidant capacity measurement method.
  • Antioxidant activity was measured using ABTS radicals by removing the ABTS free radicals produced by the reaction with potassium persulfate by the antioxidants in the sample and decolorizing the cyan color which is specific to radicals. Measured. Specifically, 7 mM 2.2-azino-bis (3-rthylbenzthiazoline-6-sulfonic acid) (ABTS) and 2.45 mM potassium persulfate were mixed at the final concentration for 24 hours in a cow at room temperature to form ABTS + radical. Diluted with distilled water at 0.9 nm so that the absorbance value is 0.9 ( ⁇ 0.1).
  • the ABST antioxidant activity of the methanol extract was observed to be about 81.17 ⁇ 0.36%
  • the chloroform fraction showed an antioxidant capacity of 72.40 ⁇ 0.24%
  • Ethyl acetate fraction showed the lowest ABST antioxidant activity of about 65.13 ⁇ 0.14%
  • n-hexan fraction showed the highest ABST antioxidant activity of 92.68 ⁇ 0.24%.
  • the total polyphenol content of the herbal extracts was analyzed based on the principle that the Folin-ciacalteu rearent was colored by molybdenum blue as a result of reduction by the polyphenol compound of the anticancer resonance group according to the method of Dewanto10).
  • To 100 ⁇ l of herbal extracts (methanol extract, chloroform fraction, ethanol fraction and hexane fraction) of each fraction add 100 ⁇ l of Folin-Ciocalteau's phenol regent, mix, hold for 3 minutes at room temperature, and add 100 ⁇ l of 2% Na 2 CO 3 solution. After mixing, the mixture was left at room temperature for 1 hour and the absorbance was measured at 750 nm.
  • Example ⁇ 4-1> In order to compare the extraction efficiency according to the solvent, the extract extracting the herbal medicine with distilled water instead of methanol in Example ⁇ 4-1> was experimented together.
  • gallic acid a standard substance, was dissolved in distilled water, and prepared according to a certain concentration, and the experiment was performed in the same manner as the sample to prepare a calibration curve and to measure the total phenol content of the sample. The results are shown in Table 3 below. It was.
  • the total phenol content of the herbal extract was 1.19 ⁇ 0.03 mg / g
  • the total phenol content of the methanol extract was about 1.19 ⁇ 0.01 mg / g.
  • the chloroform fraction showed a total phenolic content of 1.05 ⁇ 0.01 mg / g
  • the ethyl acetate fraction had a total phenolic content of about 1.17 ⁇ 0.01 mg / g
  • the n-hexan fraction had the highest total content of 1.32 ⁇ 0.01 mg / g.
  • Total phenolic content is shown.
  • the total flavonoid content of the herbal extract was 27.87 ⁇ 1.23 mg / g, and the total flavonoid content of the methanol extract was about 32.80 ⁇ 1.07 mg / g.
  • the chloroform fraction showed a total phenolic content of 30.69 ⁇ 0.72 mg / g, the ethyl acetate fraction had a total flavonoid content of about 14.09 ⁇ 0.54 mg / g, and the n-hexan fraction had a total flavonoid of 21.62 ⁇ 0.59 mg / g. Content is indicated.
  • SOD is known as an enzyme that can suppress aging by reducing superoxide to normal oxygen and various diseases such as cancer involving superoxide.
  • SOD-like activity pyrogallol is automatically oxidized by superoxide radicals in water to form a brown substance, which is analyzed by spectrophotometer, and the oxidation rate of pyrogallol is lowered in the presence of a substance having superoxide trapping activity.
  • Superoxide capture activity can be measured indirectly.
  • SOD-like activity was measured according to Markund et al.
  • Tris-HCl buffer 50 mM tris amino-methane and 10 mM EDTA adjusted to pH 8.5 in 0.2 ml (1 mg / ml concentration) of herbal extracts (methanol extract, chloroform fraction, ethanol fraction and hexane fraction) of each fraction 2.6
  • herbal extracts methanol extract, chloroform fraction, ethanol fraction and hexane fraction
  • the amount of oxidized pyrogallol in the reaction solution was measured for absorbance at 420 nm. SOD-like activity measurement was calculated by the following equation 2, the results are shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant un extrait de la plante médicinale Angelica gigas comme ingrédient actif pour la prévention ou le traitement du cancer du rein. Elle concerne plus particulièrement une composition pharmaceutique comprenant un extrait de ginseng rouge, d'Angelica gigas, de schizandra, de Semen cuscutae et de curcuma, utilisé comme ingrédient actif. Cette composition pharmaceutique, qui présente une activité antioxydante élevée, est particulièrement efficace dans la prévention du cancer du rein.
PCT/KR2011/007675 2010-10-14 2011-10-14 Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein Ceased WO2012050397A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0100151 2010-10-14
KR1020100100151A KR20120038612A (ko) 2010-10-14 2010-10-14 생약 추출물을 포함하는 신장암 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2012050397A2 true WO2012050397A2 (fr) 2012-04-19
WO2012050397A3 WO2012050397A3 (fr) 2012-08-30

Family

ID=45938824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007675 Ceased WO2012050397A2 (fr) 2010-10-14 2011-10-14 Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein

Country Status (2)

Country Link
KR (1) KR20120038612A (fr)
WO (1) WO2012050397A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103063793A (zh) * 2013-01-01 2013-04-24 吉林紫鑫药业股份有限公司 锁阳补肾胶囊的含量测定方法
CN116832105A (zh) * 2023-07-21 2023-10-03 山东惠民德赛克生物科技有限公司 一种保肾利尿的中药制剂及其制备方法
EP4265266A1 (fr) * 2023-03-16 2023-10-25 Patentpool Target GmbH Kit de pièces pour le traitement de méduloblastomes et d'astrocytomes diffus à l'aide d'extraits aqueux de cusza sp
WO2025016368A1 (fr) * 2023-07-20 2025-01-23 山东省科学院菏泽分院 Complexe d'étamine de pivoine et de semen cuscutae, son procédé de préparation et son utilisation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014069690A1 (fr) * 2012-10-31 2014-05-08 주식회사 한국전통의학연구소 Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'hedyotis diffusa
KR101898187B1 (ko) * 2017-05-11 2018-09-12 주식회사 비비씨 목단피, 구기자, 오미자를 원료로 한 항산화 및 항암 활성을 가진 복합추출물 제조방법
WO2019124604A1 (fr) * 2017-12-22 2019-06-27 경상대학교병원 Composition pharmaceutique comprenant comme principe actif de la proanthocyanidine pour la prévention ou le traitement du carcinome épidermoïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030008080A (ko) * 2001-07-16 2003-01-24 김희숙 면역증강 활성이 우수한 생약재 조성물 및 이를 포함하는기능성 식품
KR100675269B1 (ko) * 2005-07-06 2007-01-29 한국식품연구원 오미자 및/또는 산머루 추출물을 함유한 항암 치료의부작용 완화제

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103063793A (zh) * 2013-01-01 2013-04-24 吉林紫鑫药业股份有限公司 锁阳补肾胶囊的含量测定方法
EP4265266A1 (fr) * 2023-03-16 2023-10-25 Patentpool Target GmbH Kit de pièces pour le traitement de méduloblastomes et d'astrocytomes diffus à l'aide d'extraits aqueux de cusza sp
WO2024188484A1 (fr) * 2023-03-16 2024-09-19 Patentpool Target Gmbh Kit de pièces pour le traitement de médulloblastomes et d'astrocytomes diffus au moyen d'extraits alcooliques et/ou aqueux de diverses cuscuta spp.
WO2025016368A1 (fr) * 2023-07-20 2025-01-23 山东省科学院菏泽分院 Complexe d'étamine de pivoine et de semen cuscutae, son procédé de préparation et son utilisation
CN116832105A (zh) * 2023-07-21 2023-10-03 山东惠民德赛克生物科技有限公司 一种保肾利尿的中药制剂及其制备方法
CN116832105B (zh) * 2023-07-21 2024-05-14 山东惠民德赛克生物科技有限公司 一种保肾利尿的中药制剂及其制备方法

Also Published As

Publication number Publication date
KR20120038612A (ko) 2012-04-24
WO2012050397A3 (fr) 2012-08-30

Similar Documents

Publication Publication Date Title
WO2012050396A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du foie
KR101360231B1 (ko) 생약 추출물을 포함하는 간암 예방 또는 치료용 약학적 조성물
WO2012050398A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du poumon
Hussain et al. Review on ethnobotany and phytopharmacology of cordia dichotoma
WO2012050397A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein
WO2018174589A1 (fr) PROCÉDÉ POUR SOULAGER LA GINGIVITE ET LA PARODONTITE PAR ANTIBIOSE, ANTIOXYDATION, ANTI-INFLAMMATION, SUPPRESSION DE LA PERTE OSSEUSE PARODONTALE ET RÉGÉNÉRATION DE L'OS PARODONTAL AU MOYEN D'UN COMPLEXE D'EXTRAIT DE FEUILLE DE MORINGA OLEIFERA ET D'EXTRAIT D'EUCOMMIA ULMOIDES <i /><i />
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
KR101794006B1 (ko) 식물 추출물을 포함하는 염증 개선용 조성물
WO2016167577A1 (fr) Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur
KR101360232B1 (ko) 생약 추출물을 포함하는 신장암 예방 또는 치료용 약학적 조성물
McCalla et al. Physiologic effects of Hibiscus sabdariffa (Sorrel) on biological systems: Advances in Sorrel research
Srivastava et al. Natural products and derivatives: Biological and pharmacological activities
KR101833776B1 (ko) 지모와 두릅의 복합 추출물을 함유하는 탈모 방지 및 발모 개선용 조성물
KR101360233B1 (ko) 생약 추출물을 포함하는 폐암 예방 또는 치료용 약학적 조성물
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
KR102663306B1 (ko) 치주질환 예방, 개선 또는 치료용 조성물
Teja et al. Phytochemical and In vitro Anti-inflammatory Activity on Abrus precatorius
JP7361903B2 (ja) 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物
KR20040008975A (ko) 뇌기능 및 인지 기능 개선 활성을 갖는 조성물
Papang et al. Pharmacological Properties and Therapeutic Potential of Urtica dioica: A Comprehensive Review
KR102617383B1 (ko) 석류, 마 및 둥굴레의 혼합 추출물을 이용한 항비만용 조성물 및 그 제조방법
KR102362903B1 (ko) 천연소재 추출물 함유 식품 조성물 및 그의 제조 방법
Chandrakar et al. A therapeutic potentiality and toxicity concern of nutrient plant Annona squamosa Linn
KR101404036B1 (ko) 망막질환 예방 및 치료에 유용한 이고들빼기 추출물
Khadka et al. Pharmacognostic and pharmacological review on Choerospondias axillaris

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832784

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11832784

Country of ref document: EP

Kind code of ref document: A2